Tags

Type your tag names separated by a space and hit enter

Clinical experience with pentoxifylline in occlusive cerebrovascular disorders.

Abstract

Pentoxifylline--3,7-dimethyl-1(5-oxo-hexyl) xanthine--a new vasodilator compound, was tried in 28 cases of occlusive cerebrovascular disease. A similar group of 24 patients were given xanthinol nicotinate. Although in terms of degree of improvement there was no significant difference in the two treatment groups, improvement was earlier in the group treated with pentoxifylline. No significant side effects were observed with any of the two drugs used in the present study.

Links

  • Publisher Full Text
  • Authors

    ,

    Source

    Angiology 28:5 1977 May pg 340-5

    MeSH

    Adult
    Cerebrovascular Disorders
    Female
    Hemiplegia
    Humans
    Ischemic Attack, Transient
    Male
    Motor Activity
    Pentoxifylline
    Speech Disorders
    Theobromine

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    869291

    Citation

    Sen, S, and A Chakravarty. "Clinical Experience With Pentoxifylline in Occlusive Cerebrovascular Disorders." Angiology, vol. 28, no. 5, 1977, pp. 340-5.
    Sen S, Chakravarty A. Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. Angiology. 1977;28(5):340-5.
    Sen, S., & Chakravarty, A. (1977). Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. Angiology, 28(5), pp. 340-5.
    Sen S, Chakravarty A. Clinical Experience With Pentoxifylline in Occlusive Cerebrovascular Disorders. Angiology. 1977;28(5):340-5. PubMed PMID: 869291.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. AU - Sen,S, AU - Chakravarty,A, PY - 1977/5/1/pubmed PY - 1977/5/1/medline PY - 1977/5/1/entrez SP - 340 EP - 5 JF - Angiology JO - Angiology VL - 28 IS - 5 N2 - Pentoxifylline--3,7-dimethyl-1(5-oxo-hexyl) xanthine--a new vasodilator compound, was tried in 28 cases of occlusive cerebrovascular disease. A similar group of 24 patients were given xanthinol nicotinate. Although in terms of degree of improvement there was no significant difference in the two treatment groups, improvement was earlier in the group treated with pentoxifylline. No significant side effects were observed with any of the two drugs used in the present study. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/869291/Clinical_experience_with_pentoxifylline_in_occlusive_cerebrovascular_disorders_ L2 - http://journals.sagepub.com/doi/full/10.1177/000331977702800505?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -